BioCentury
ARTICLE | Clinical News

Capmatinib: Phase II data

May 30, 2016 7:00 AM UTC

Data from 28 patients with advanced c-MET dysregulated HCC in the dose-expansion cohort of an open-label, Asian Phase II trial showed that twice-daily 600 mg oral capmatinib led to an ORR of 11%, incl...